Zevra Therapeutics (ZVRA) Set to Announce Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) is scheduled to release its earnings data after the market closes on Tuesday, August 13th. Analysts expect Zevra Therapeutics to post earnings of ($0.47) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. The business had revenue of $3.43 million during the quarter, compared to analyst estimates of $3.52 million. Zevra Therapeutics had a negative net margin of 181.76% and a negative return on equity of 82.55%. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Up 0.6 %

ZVRA traded up $0.05 during trading hours on Tuesday, reaching $7.93. 836,472 shares of the stock traded hands, compared to its average volume of 372,701. The firm’s fifty day simple moving average is $5.19 and its two-hundred day simple moving average is $5.43. The company has a market cap of $331.89 million, a price-to-earnings ratio of -5.92 and a beta of 1.97. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $8.44. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.10 and a quick ratio of 2.10.

Insider Activity at Zevra Therapeutics

In other news, Director Thomas Anderson acquired 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The shares were purchased at an average cost of $6.81 per share, for a total transaction of $68,100.00. Following the transaction, the director now directly owns 20,000 shares in the company, valued at approximately $136,200. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought a total of 22,000 shares of company stock worth $140,340 in the last ninety days. 2.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ZVRA. HC Wainwright raised their price target on shares of Zevra Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Monday. Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a report on Monday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $20.25.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.